Logo image of NVS

NOVARTIS AG-SPONSORED ADR (NVS) Stock Price, Quote, News and Summary

NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR

99.73  +2.2 (+2.26%)

After market: 98.8 -0.93 (-0.93%)

NVS Quote and Key Statistics

NOVARTIS AG-SPONSORED ADR

NYSE:NVS (1/21/2025, 6:40:00 PM)

After market: 98.8 -0.93 (-0.93%)

99.73

+2.2 (+2.26%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High120.92
52 Week Low92.35
Market Cap199.39B
Shares2.00B
Float1.74B
Yearly Dividend3.48
Dividend Yield3.64%
PE13.37
Fwd PE11.81
Earnings (Next)01-31 2025-01-31/amc
IPO05-07 2001-05-07

NVS Financial Highlights

Industry RankSector Rank
PM (TTM) 35.25%
ROA 18.66%
ROE 44.37%
Debt/Equity 0.47
Chartmill High Growth Momentum
EPS Q2Q%12.57%
Sales Q2Q%8.84%
EPS 1Y (TTM)6.82%
Revenue 1Y (TTM)-18.26%
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVS Performance and Technical Analysis

Chartmill TA Rating
Chartmill Setup Rating

NVS short term performance overview.The bars show the price performance of NVS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10

NVS long term performance overview.The bars show the price performance of NVS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 10
NVS Daily chart

NVS Ownership and Analysts

Ownership
Inst Owners39.02%
Ins Owners0.01%
Short Float %0.23%
Short Ratio3.37
Analysts
Analysts69.66
Price Target117.9 (18.22%)
EPS Next Y11.87%
Revenue Next Year7.89%

NVS Latest News and Analysis

News Image
12 days ago - Chartmill

Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag.

Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents.

News Image
18 days ago - Chartmill

Balancing Dividends and Fundamentals: The Case of NYSE:NVS.

Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.

News Image
10 hours ago - Bloomberg

JPMorgan's Gori On Trump & 'Incredible' US Economy | Bloomberg The Pulse 01/21

Live from the 2025 World Economic Forum in Davos, we speak to business leaders and central bankers as Donald Trump returns to the White House. JP Morgan's EMEA CEO Filippo Gori says European clients share a split sentiment on the possible outcomes of a second Trump presidency. Also on the show, the Bank of France Governor, Francois Villeroy De Galhau, says the current trend of European disinflation means the ECB may not need to quicken or expand interest rate cuts. Today's guests: Filippo Gori, JP Morgan Chase EMEA CEO & Co-Head of Global Banking; Vas Narasimhan, Novartis CEO; Ron O'Hanley, State Street Chairman & CEO; Francois Villeroy De Galhau, Bank of France Governor (Source: Bloomberg)

News Image
13 hours ago - Bloomberg

Novartis CEO Says Concerns on Trump Health Policy Are Overblown

Moves by the incoming Trump Administration may be a boon to drugmakers, Novartis AG Chief Executive Officer Vas Narasimhan said, while concerns over vaccine policies and public health funding are “overblown.”

News Image
5 days ago - Yahoo Finance

US appeals court lifts pause on generic version of Novartis' Entresto

Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch. The U.S. Court of Appeals for the District of Columbia Circuit lifted the pause less than 24 hours after it started, potentially freeing MSN to launch its generic in the U.S. amid an ongoing patent dispute between the companies. Spokespeople and an attorney for Novartis did not immediately respond to a request for comment and more information on the ruling.

News Image
5 days ago - Benzinga

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.

About NVS

Company Profile

NVS logo image Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 76,057 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company Info

NOVARTIS AG-SPONSORED ADR

Lichtstrasse 35

Basel BASEL-STADT CH 4056 CH

CEO: Vasant (Vas) Narasimhan

Employees: 76057

Company Website: https://www.novartis.com/

Investor Relations: https://www.novartis.com/investors

Phone: 41613241111

NVS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 72.99 704.73B
NVO NOVO-NORDISK A/S-SPONS ADR 27.56 359.88B
JNJ JOHNSON & JOHNSON 14.47 356.69B
MRK MERCK & CO. INC. 16.17 243.45B
AZN ASTRAZENECA PLC-SPONS ADR 17.84 210.75B
PFE PFIZER INC 10.33 150.97B
SNY SANOFI-ADR 12.49 129.60B
BMY BRISTOL-MYERS SQUIBB CO 48.75 115.69B
ZTS ZOETIS INC 29.09 75.58B
GSK GSK PLC-SPON ADR 8.3 68.92B
TAK TAKEDA PHARMACEUTIC-SP ADR 21.83 41.53B
TEVA TEVA PHARMACEUTICAL-SP ADR 7.85 24.72B